You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu


AZ says MPO inhibitor AZD4831 shows promise in heart failure study

AstraZeneca (AZ) has revealed results from a mid-stage study of its investigational myeloperoxidase (MPO) inhibitor in patients with heart failure with preserved ejection fraction (HFpEF).